Whether facilitating lower extremity revascularization or providing vascular access, the versatile GORE® PROPATEN® Vascular Graft is purposefully designed to improve outcomes and reduce reinterventions. With more than a decade of strong performance, this trusted vascular graft provides proven clinical and economic value. 

Bypass procedures

Provide significant benefits in lower extremity bypass procedures.

 

Learn More

Vascular access

Offer an individualized approach to access creation for patients at risk of fistula maturation challenges.
 

See how

Bypass procedures

Leadership in lower extremity bypasses


600K+ Devices implanted | 2,000+ Limbs studied

With more than 600,000 devices implanted over a span of more than 10 years ─ and over 2,000 limbs studies ─ the GORE® PROPATEN® Vascular Graft is a clinically proven prosthetic bypass graft solution, both for performance and for low cumulative cost of care.


Proven patency

Above-knee bypass primary patency
Above-knee bypass primary patency

Above-knee data

Below-knee bypass primary patency
Below-knee bypass primary patency

Below-knee data


By substantially reducing acute graft thrombosis within hours after implantation, the GORE® PROPATEN® Vascular Graft provides clinical benefits that standard expanded polytetrafluoroethylene (ePTFE) grafts do not.1


Fewer occlusions
50% reduction in risk of graft occlusion compared to standard ePTFE in critical limb ischemia (CLI) patients.2


Improved patient outcomes
Higher primary and secondary patency, and higher limb salvage for below-knee bypass compared to standard ePTFE from 1–3 years.3

Improved clinical outcomes


Measurable value

A clinically proven prosthetic bypass graft solution, the GORE® PROPATEN® Vascular Graft also facilitates a low cumulative cost of care. 


 

Low treatment cost

Long-term valueII

28% Patients

Improvement in
amputation-free survival

36% Physicians

Decrease in revision procedures

38% Providers

Decrease in average costs

Vascular access

A trusted choice for vascular access


200K+ devices implanted, 100+ clinical publications

From fistula-first to patient-first

Todays’ end-stage renal disease (ESRD) patients have greater heterogeneity than ever. That’s one reason 2019 Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines5 emphasize the need for more individualized approach to access modality selection. 

When your hemodialysis patients are at risk of fistula non-maturation, the GORE® PROPATEN® Vascular Graft can provide confidence and proven results. 

  • Trusted by physicians more than any other vascular graft6
  • Reported potential to improve primary patency by up to 20%**,7

With patency you can count on, you can give your patients reliable vascular access for the road ahead.

  • Reduce the need for central venous catheters (CVCs)8
  • Reduce unnecessary access-related procedures9

Lasting thromboresistance10

The CBAS Heparin Surface consists of a proprietary covalent end-point bond that preserves the active site, thus retaining heparin’s anticoagulant activity.
 

Reported ability to significantly reduce early thrombosis rates **, 11 78% clot-free survival reported at one year7

Proven

Heparin availability

Performance-ready heparin active site.4,12


Proven

Heparin bioactivity

Unmatched, persistent ability to take up antithrombin.1,13


Proven

Lasting thromboresistance

Improved surface hemocompatibility resulting from heparin availability and bioactivity.1,4,10,12,13




Sustained heparin bioactivity8

In vivo canine carotid artery interposition model

The CBAS Heparin Surface of a 3 mm diameter GORE® PROPATEN® Vascular Graft (top) remains free of thrombus, while the 3 mm diameter control ePTFE graft (bottom) is covered with thrombus in an acute two-hour in vivo canine carotid artery interposition model.

Learn more about CBAS

* Overall weighted average primary patency is based on data from 14 peer-reviewed publications meeting pre-determined inclusion criteria. Visit goremedical.com/propaten to see inclusion criteria. Visit goremedical.com/propaten to see inclusion criteria, explore the data and see publications.

 Weighted average of GORE® PROPATEN® Vascular Graft data. Visit goremedical.com/propaten to see inclusion criteria, explore the data and see publications.

ǂ Weighted average of standard ePTFE data. Visit goremedical.com/propaten to see inclusion criteria, explore the data and see publications.

§ Procedures for restoring flow in stenosed or occluded graft.

II Based on the three-year published clinical performance and economic model.

Replacing the graft with the new graft.

** Compared with standard non-heparin bonded ePTFE grafts.

  1.  Begovac PC, Thomson RC, Fisher JL, Hughson A, Gällhagen A. Improvements in GORE-TEX® Vascular Graft performance by Carmeda® BioActive Surface heparin immobilization. European Journal of Vascular & Endovascular Surgery 2003;25(5):432-437.
  2.  Lindholt JS, Gottschalksen B, Johannesen N, et al. The Scandinavian PROPATEN® Trial – 1-year patency of PTFE vascular prostheses with heparin-bonded luminal surfaces compared to ordinary pure PTFE vascular prostheses – a randomized clinical controlled multi-centre trial. European Journal of Vascular & Endovascular Surgery 2011;41(5):668-673.
  3.  GORE® PROPATEN® Vascular Graft. W. L. Gore & Associates Web site. https://www.goremedical.com/propaten/references. Accessed May 15, 2019.
  4.  Gore S, Andersson J, Biran R, Underwood C, Riesenfeld J. Heparin surfaces: impact of immobilization chemistry on hemocompatibility and protein adsorption. Journal of Biomedical Materials Research Part B: Applied Biomaterials 2014;102(8):1817-1824.
  5.   Lok CE, Huber TS, Lee T, et al; KDOQI Vascular Access Guideline Work Group. KDOQI Clinical Practice Guideline for Vascular Access: 2019 update.  American Journal of Kidney Diseases 2020;75(4)Supplement 2:S1-S164.
  6.  Decision Resources Group (DRG) Market Insights Database. MedTech 360 Dialysis Access Treatment Devices, US; Sept 2020.
  7.  Journal of Vascular Access 2009 Jul-Sept;10(3):153-6. Doi: 10.1177/112972980901000303. PMID: 19670166.
  8.  Al-Balas A, Lee T, Young CJ, Kepes JA, Barker-Finkel J, Allon M. The clinical and economic effect of vascular access selection in patients initiating hemodialysis with a catheter. Journal of the American Society of Nephrology 2017;28(12):3679-3687.
  9.  Mohr BA, Trovillion PJ. Economic value of preventing central venous catheter sepsis infections with early cannulation arteriovenous grafts (ECAVGS) compared to non-ecavgs. Presented at the ISPOR 20TH Annual International Meeting; May 16-20, 2015; Phildelphia, PA. Value in Health 2015;18(3):A42. PMD27.
  10.  Decision Resources Group (DRG) Market Insights Database. MedTech 360 Dialysis Access Treatment Devices, US; Sept 2020.
  11.  et al. A prospective randomized study of heparin-bonded graft (Propaten) versus standard graft in prosthetic arteriovenous access. Journal of Vascular Surgery 2015 Jul;62(1):115-22. Doi:10.1016/j.jvs.2015.01.056. Epub 2015 Mar 12. PMID: 25770987.
  12.  Biran R, Pon D. Heparin coatings for improving blood compatibility of medical devices. Advanced Drug Delivery Reviews 2017;112:12-23.
  13.  Freeman J, Chen A, Weinberg RJ, Okada T, Chen C, Lin PH. Sustained thromboresistant bioactivity with reduced intimal hyperplasia of heparin-bonded PTFE Propaten Graft in a chronic Canine femoral artery bypass model. Annals of Vascular Surgery 2018;49:295-303.
  14.  Biran R. Heparin Activity and Concentration Values from 52 and 96 Month Duration Clinical Explants of the GORE® PROPATEN® Vascular Graft. Flagstaff, AZ: W.L. Gore & Associates, Inc; 2011 [Work plan]. WP104647.

GORE PROPATEN Vascular Graft